Nearly four decades ago, King et al. reported that a novel candidate oncogene, ERBB2 — also designated c-neu — which encodes human epidermal growth factor receptor 2 (HER2), is amplified up to 20-fold in a subset of human mammary carcinomas (1). Here, ERBB2 is linked to breast carcinoma.